|
Dr. Jeffrey Wigle
Principal Investigator, Vascular Development
Institute of Cardiovascular Sciences
In Detail
Dr. Jeffrey Wigle is a developmental biologist who is studying the cell cycle of adult differentiated vascular smooth muscle cells. His research focuses on how homeobox transcription factors control vascular growth during both embryonic development and during disease progression. Since many of the growth pathways used by fetal blood vessels are re-utilized in adults during disease, we can understand the disease processes by determining how the vessels grow during embryonic development. Dr. Wigle’s laboratory is studying the genes that control the growth of blood vessels (Meox1/Meox2) and that control the growth of lymphatic vessels (Prox1).
The lymphatic vasculature is a thin-walled, permeable system that functions to re-absorb protein rich extracellular fluid and returns this fluid to the circulatory system. Disruption of the lymphatic vasculature results in the accumulation of extracellular fluid and leads to diseases known as lymphedemas. Primary lymphedemas arise from a genetic cause and can vary in their onset and severity. In Canada, secondary lymphedema is a common, painful side effect that occurs when lymphatic nodes and vessels are destroyed during breast cancer therapy. In cancer, metastatic cells can enter the lymphatic circulation and escape the site of the original tumour. The degree of lymphatic vascularization has been correlated in animal models and human studies with the tendency of tumour cells to disseminate. Regulating lymphatic growth represents a novel therapy target for the treatment of lymphedema or metastatic tumours. In Prox1 knockout mice, it has previously been demonstrated that the cells, which would normally become lymphatic endothelial cells, instead became blood endothelial cells. One of the goals of his research is to determine how Prox1 functions as a cell fate switch and thus regulates lymphatic vessel growth. By determining what genes are regulated by Prox1 directly and what genes are indirectly regulated, he will determine how Prox1 regulates the growth of lymphatic vessels. Dr. Wigle’s work in establishing how Prox1 can regulate the cell fate choices made by endothelial cells during development will lead to better ways of regulating lymphatic growth during disease states and embryonic development.
Meox1/Meox2 are homeobox genes that are expressed early in the developing mesoderm. The homeodomains of these two proteins are nearly identical however regions outside of this domain are not conserved at all. Meox2 (also known as Gax) was shown to be downregulated at both the mRNA and protein levels when vascular smooth muscle cells (VSMCs) are stimulated to proliferate with growth factors. Ectopic expression of Meox2 protein attenuates VSMC growth by blocking proliferation and inducing apoptosis. In vivo, these effects lead to decreased vessel blockage (restenosis) in rodent models of balloon angioplasty. Recently, Meox2 expression was shown to be decreased in endothelial cells derived from blood vessels of Alzheimer disease patients. Meox2 was required to maintain the ability of the endothelial cells to grow. Dr. Wigle and his laboratory are determining the molecular mechanisms used by Meox2 and Meox1 to regulate VSMC and endothelial cell growth.
For more information, please contact:
Dr. Jeffrey Wigle
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
|
